|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The imaging potential of the CD133-targeted IgG (HA10 IgG) was evaluated in preclinical prostate cancer models using two different imaging modalities: near-infrared and positron emission tomography (PET) imaging.
|
31732520 |
2020 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we examined whether ectopic overexpression of CD133, a key molecule maintaining the stability of CSCs in the human PC cell line, LnCaP, caused bone metastasis in a mouse model.
|
31423179 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Delivery Of Curcumin Nanoliposomes Using Surface Modified With CD133 Aptamers For Prostate Cancer.
|
31819373 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of Two Types of Stem Cells in Methylene Blue-stained Sections of Untreated and Diethylstilbestrol-treated Human Prostate Cancer and Their Characterization by Immunogold Localization of CD133.
|
30275193 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our preliminary investigation also suggests that there may be an association between CD133 and non-AR driven prostate cancer with neuroendocrine differentiation.
|
29790189 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
|
29775627 |
2018 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
|
28600675 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A significant reciprocal correlation was observed between the expression of two putative CSC markers CD44 and CD133 in PCa specimens while not indicating clinical significance.
|
28083789 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD44+CD133+α2β1Integrin+CD24- population was isolated from mock or TGF-β treated (7 days) prostate cancer cell line, LNCaP, through fluorescent activated cell sorting.
|
25661993 |
2015 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting TR4 with lentiviral silencing RNA significantly suppressed prostate cancer CD133(+) S/P cell invasion both in vitro and in vivo.
|
25833838 |
2015 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, cluster of differentiation 133 (CD133)(+high)/CD44(+high) prostate CSCs were isolated from the DU145 human prostate cancer cell line.
|
25216351 |
2014 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of TR4 levels in the established PCa stem/progenitor cells and the CD133(+) population of the C4-2 PCa cell line with lentiviral TR4 siRNA led to increased drug sensitivity to the two commonly used chemotherapeutic drugs, docetaxel and etoposide, judging from significantly reduced IC50 values and increased apoptosis in the TR4 knockdown cells.
|
23609451 |
2013 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, AR79 increased the ALDH(+)CD133(+) cancer stem cell-like proportion of the prostate cancer cell lines.
|
24088787 |
2013 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we re-investigated its general expression in male reproductive tract including mouse and human prostate and in prostate cancer samples using various anti-prominin-1 antibodies.
|
20717901 |
2011 |
|
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We found that CD133 expression is repressed by DNA methylation in the majority of prostate epithelial cell lines examined, where the promoter is heavily CpG hypermethylated, whereas in primary prostate cancer and benign prostatic hyperplasia, low levels of DNA methylation, accompanied by low levels of mRNA, were found.
|
21801380 |
2011 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that inhibition of PI3K activity by the dual PI3K/mTOR inhibitor NVP-BEZ235 leads to a decrease in the population of CD133(+)/CD44(+) prostate cancer progenitor cells in vivo.
|
21138868 |
2010 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These signaling molecules were also present in the bulk tumor mass of CD133(-) prostate cancer cells with a luminal phenotype detected in patient's adenocarcinoma tissues.
|
20179163 |
2010 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously shown that rare prostate epithelial cells with a CD133+/alpha2beta1hi phenotype have the properties of prostate cancer stem cells.
|
18492237 |
2008 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TGFBR3 knockdown led to focus formation and enhanced expression of CD133, a marker found on prostate cancer stem cells.
|
17192875 |
2007 |